(ARQT) Arcutis Biotherapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ARQT) Arcutis Biotherapeutics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Arcutis Biotherapeutics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it easier to assess growth and capital allocation. The page already includes a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
ZORYVE cream 0.3% plaque psoriasis
ZORYVE cream 0.3% is the FDA-approved roflumilast cream for plaque psoriasis, and it is Arcutis Biotherapeutics, Inc.’s lead commercial brand. It sits in the clearest Star slot in 2025 because it is the company’s main growth driver in dermatology, with a 0.3% strength built for chronic plaque psoriasis demand.
ZORYVE cream 0.15% atopic dermatitis
ZORYVE cream 0.15% is the U.S.-approved topical roflumilast for atopic dermatitis, approved by the FDA in July 2024. Atopic dermatitis affects about 31.6 million people in the U.S., so it is a large and still growing prescription market. The launch broadens Arcutis Biotherapeutics, Inc. beyond psoriasis and strengthens its Stars position.
ZORYVE cream 0.3% inverse psoriasis
ZORYVE cream 0.3% gained a U.S. inverse psoriasis label, adding a second psoriasis use to Arcutis Biotherapeutics, Inc.'s roflumilast platform. Inverse psoriasis affects skin folds and is a niche segment, so this broadens the same branded franchise without a new molecule. That kind of label expansion can deepen reach in a high-value dermatology market.
ZORYVE foam 0.3% seborrheic dermatitis
ZORYVE foam 0.3% is the U.S.-approved roflumilast foam for seborrheic dermatitis, cleared by the FDA in June 2024 for patients 9 years and older. Its foam form helps treat scalp and other hair-bearing areas, so it fits a wider real-world use case than creams. That makes it a clear growth driver for Arcutis Biotherapeutics, Inc.'s brand family.
- U.S. approved, 9+ years
- Foam reaches scalp areas
- Supports brand expansion
ZORYVE foam 0.3% plaque psoriasis
ZORYVE foam 0.3% is Arcutis Biotherapeutics, Inc.’s US-approved foam for plaque psoriasis, adding a second delivery format to the same core market. In 2024, ZORYVE net product revenue reached $176.4 million, up 168% year over year, and the foam helps widen reach, support share gains, and deepen brand use.
It fits the Star bucket because it pairs strong market growth with rising franchise pull. Arcutis also reported 2024 total revenue of $176.9 million, with ZORYVE the main driver, and the foam can help convert more patients who prefer a leave-on format.
- US-approved plaque psoriasis foam
- Second ZORYVE delivery format
- Helps expand brand reach
- Supports share gains in core market
ZORYVE: Arcutis’ breakout growth engine across three markets
ZORYVE is Arcutis Biotherapeutics, Inc.’s Star franchise: cream 0.3% for plaque psoriasis, cream 0.15% for atopic dermatitis, and foam 0.3% for scalp-prone seborrheic dermatitis. The brand drove 2024 net product revenue of $176.4 million, up 168% year over year, and total revenue of $176.9 million.
| Star asset | Use | Why it matters |
|---|---|---|
| ZORYVE cream 0.3% | Plaque psoriasis | Lead growth driver |
| ZORYVE cream 0.15% | Atopic dermatitis | Expands addressable market |
| ZORYVE foam 0.3% | Seborrheic dermatitis | Broadens delivery format |
What is included in the product
Detailed Word Document
Arcutis Biotherapeutics’ BCG Matrix maps its dermatology products by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG Matrix for Arcutis Biotherapeutics, Inc. to quickly spot winners, cash drains, and next moves.
Reference Sources
Provides a traceable source trail for Arcutis Biotherapeutics, Inc. insights, boosting credibility and speeding better investment decisions.
Cash Cows
ZORYVE plaque psoriasis refill base
ZORYVE plaque psoriasis refills are the core cash cow for Arcutis Biotherapeutics, Inc., because plaque psoriasis is chronic and repeat prescriptions support recurring revenue. In 2024, Arcutis reported net product revenue of about $250 million, and ZORYVE was the main driver. The refill base is the most cash-generating commercial layer in the portfolio, with retention mattering more than one-time starts.
ZORYVE inverse psoriasis maintenance use
ZORYVE’s use in inverse psoriasis fits the Cash Cow box because it treats a chronic inflammatory condition, so patients often stay on therapy. Arcutis Biotherapeutics, Inc.’s once-daily, nonsteroidal roflumilast offers durable maintenance value after start-up, which supports repeat prescribing.
That makes it more cash-like than a pipeline asset: demand can recur month after month, with lower launch risk once access and response are established.
ZORYVE seborrheic dermatitis chronic care
ZORYVE seborrheic dermatitis fits Cash Cows because seborrheic dermatitis is chronic and often needs repeat treatment, so refill demand can stay steady. The U.S. FDA approved ZORYVE foam 0.3% for seborrheic dermatitis in 2023, and ongoing prescribing lowers launch spend over time. That supports durable cash flow as Arcutis Biotherapeutics, Inc. builds a repeat-use brand in a condition affecting about 3% to 5% of adults.
Dermatology specialty sales force
Arcutis Biotherapeutics, Inc. built a dedicated dermatology sales force, so the fixed selling cost can support multiple ZORYVE launches without a full rebuild each time. That scale effect helps turn rising product revenue into operating cash as the field team covers more prescribers and uses the same commercial base across indications.
- Fixed team, multiple ZORYVE launches
- Lower launch cost per product
- Better conversion of sales to cash
Roflumilast manufacturing platform
Arcutis Biotherapeutics, Inc. uses the same topical active ingredient, roflumilast, across its ZORYVE line, so one manufacturing base can support multiple formulations. That shared supply chain should lower unit costs as volume grows, which helps a Cash Cow platform keep margins improving without a matching jump in fixed spend.
- One API across formulations
- Shared plants and supply chain
- Higher volume can raise margins
- Supports a scalable cash engine
ZORYVE Refills Drive Arcutis’s Steady Revenue
ZORYVE refills remain Arcutis Biotherapeutics, Inc.’s main Cash Cow, because chronic plaque psoriasis, inverse psoriasis, and seborrheic dermatitis drive repeat use. Arcutis Biotherapeutics, Inc. reported about $250 million in 2024 net product revenue, led by ZORYVE. A shared roflumilast platform and one dermatology sales force help turn repeat scripts into steadier cash.
| Metric | Data |
|---|---|
| 2024 net product revenue | ~$250 million |
| Core Cash Cow | ZORYVE refills |
Get Your Copy
Arcutis Biotherapeutics, Inc. Reference Sources
You’re previewing the exact Arcutis Biotherapeutics, Inc. BCG Matrix report you’ll receive after purchase. The file is the same fully formatted document—no placeholders, no demo content, and no watermarks. Once purchased, it’s ready to download, edit, print, or share right away.
Dogs
No legacy commercial brands
Arcutis had no meaningful legacy commercial brands in 2025; ZORYVE generated $177.8 million in net product revenue in 2024 and remained the core asset. With no old-brand revenue base to defend, the Dogs bucket is minimal. The mix is concentrated in ZORYVE plus pipeline assets, not a long tail of low-share brands.
No biologic franchise
Arcutis Biotherapeutics, Inc. has no injectable biologic franchise, so there is no mature biologic brand to tag as a "Dog". Its business is built on topical dermatology, led by ZORYVE (roflumilast) cream and foam, not biologics. That makes the BCG "Dog" bucket largely irrelevant here.
No OTC consumer line
Arcutis Biotherapeutics, Inc. is a prescription dermatology company, not an OTC skin-care brand. Its portfolio centers on ZORYVE cream 0.15% and 0.3%, plus ZORYVE foam 0.3%, so it stays in higher-value Rx channels. That keeps Arcutis away from a weak, low-margin consumer tail that would dilute the BCG profile.
No major non-dermatology segment
Arcutis Biotherapeutics, Inc. is tightly focused on skin disease, with zero major non-dermatology segment in 2025 and no unrelated therapy line to drag on capital. That keeps the Dogs risk low: there is no stranded low-growth unit outside dermatology, and 100% of the business is still tied to skin-care demand and product execution.
- 100% dermatology focus in 2025.
- No unrelated therapeutic segment.
- Lower risk of stranded assets.
No large divested product base
Arcutis Biotherapeutics, Inc. had a very compact 2025 portfolio: 1 commercial brand, ZORYVE, and no broad legacy line to prune. That means the Dogs bucket is thin, because there is no large set of aging, low-return assets in the disclosed mix. As of end-2025, no major dog asset was visible in the public portfolio.
- 1 core commercial product
- No large divested legacy base
- Dogs exposure stays limited
Arcutis Has Minimal Dogs Exposure, Backed by ZORYVE Growth
Arcutis Biotherapeutics, Inc. has almost no Dogs exposure in 2025: it had 1 core commercial product, ZORYVE, and no major legacy or unrelated brands to drag down returns. Net product revenue reached $177.8 million in 2024, and the portfolio stayed concentrated in dermatology, so weak low-share assets were not a meaningful issue.
| Metric | Value |
|---|---|
| Commercial products | 1 |
| Net product revenue | $177.8M |
| Dogs exposure | Minimal |
Question Marks
ARQ-252 hand eczema
ARQ-252 is Arcutis Biotherapeutics, Inc.'s topical selective JAK1 inhibitor candidate for hand eczema, a chronic condition affecting about 4% to 10% of adults worldwide and often tied to work loss and poor quality of life. The market is still fragmented and no product has clear share leadership, so ARQ-252 remains a Question Mark until efficacy, safety, and commercial uptake are proven.
ARQ-252 vitiligo
ARQ-252 in vitiligo is still a Question Mark for Arcutis Biotherapeutics, Inc. The ARQ-252 platform is in development, while global vitiligo affects about 0.5% to 2% of people, so the market is real but still being shaped by new data. With several pipeline-stage rivals and limited clinical proof so far, ARQ-252 needs stronger trial results and clearer physician uptake.
ARQ-255 alopecia areata
ARQ-255 is a deeper-penetrating follow-on to ARQ-252 for alopecia areata, a disease that affects about 2% of people worldwide at some point in life. The program sits in the Question Mark box because the upside is real, but clinical and commercial proof is still limited. In a market now shaped by 3 FDA-approved systemic options, ARQ-255 still needs data to win share.
Next roflumilast label expansion
Roflumilast label expansion stays a Question Mark for Arcutis Biotherapeutics, Inc. because each new ZORYVE indication could add revenue without a new molecule, but approval risk remains. The upside is real: one brand can scale across more skin diseases and widen prescriber reach. Until regulators approve the next use, the revenue case is still unproven.
More labels, same molecule.
Approval risk keeps it a Question Mark.
Each win can lift ZORYVE sales.
Ex-US expansion opportunity
Arcutis Biotherapeutics, Inc. is still mostly a US story: ZORYVE is commercialized in the US only, so ex-US expansion could add a new revenue lane. That makes this a classic Question Mark in BCG terms: high upside, but no international sales base yet. Until Arcutis signs partners or launches abroad, the opportunity stays open, not proven.
- US-only commercial footprint
- International launches not yet secured
- New markets could lift growth
- Still a Question Mark today
Arcutis’ Question Marks Could Drive the Next Growth Wave
Arcutis Biotherapeutics, Inc. Question Marks are ARQ-252, ARQ-255, roflumilast label expansion, and ex-US ZORYVE growth: each has upside, but none has proven share yet. Hand eczema affects about 4% to 10% of adults, vitiligo 0.5% to 2% of people, and alopecia areata about 2% at some point in life.
| Asset | Why Question Mark | Market cue |
|---|---|---|
| ARQ-252 | Early clinical proof | Hand eczema, 4% to 10% |
| ARQ-255 | Limited data | Alopecia areata, about 2% |
| ZORYVE | More labels needed | US only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.